Evidence map›Paper›PMID 41809386›Full record

ArticleMaterials today. Bio2026

Transdermal siRNA delivery via biomineralized nanoparticle-incorporated microneedles modulates cuproptosis-ferroptosis interaction for psoriasis therapy.

Lu Hao, Pian Yu, Rongxuan Yan, Kaixuan Li, Zhisheng Luo, Shijun Xiang, Yilan Wang, Chi Fang, Guanming Wang, Sihui Ma and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lu HaoDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, Hunan, 410008, China.
Pian YuThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, 410000, China.
Rongxuan YanThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, 410000, China.
Kaixuan LiThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, 410000, China.
Zhisheng LuoDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, Hunan, 410008, China.
Shijun XiangDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, Hunan, 410008, China.
Yilan WangDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, Hunan, 410008, China.
Chi FangThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, 410000, China.
Guanming WangThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, 410000, China.
Sihui MaThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, 410000, China.
Cong PengThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, 410000, China.
Shuo HuDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, Hunan, 410008, China.
Peng LiuDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, Hunan, 410008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis is a chronic immune-mediated skin disorder driven by abnormal keratinocyte proliferation and inflammation, and the dysregulation of copper transport is increasingly recognized as a key metabolic driver and potential therapeutic target in psoriasis. Herein, we identified solute carrier family 31 member 1 (SLC31A1) as a pivotal molecular switch connecting cuproptosis and ferroptosis, two interconnected forms of regulated cell death that synergistically promote psoriatic pathology. Upregulated SLC31A1 induces copper accumulation and elevates α-ketoglutarate (α-KG), activating KDM5B-dependent histone demethylation and repressing FTH1 transcription, thereby amplifying ferroptotic damage and inflammation. To therapeutically target this axis, we developed a nanoparticle-incorporated microneedle system (CaP-siSlc31a1@MN) enabling localized, efficient and minimally invasive siRNA delivery through the psoriatic barrier. The dissolvable microneedles with favorable mechanical performance ensured precise epidermal deposition, while biomineralized calcium phosphate (CaP) nanoparticles facilitated intracellular uptake and siRNA release. In vitro and in vivo studies confirmed that CaP-siSlc31a1@MN effectively silenced Slc31a1, inhibited cuproptosis and ferroptosis, suppressed IL17A-driven inflammation and restored epidermal homeostasis. Overall, this study introduces a first-in-class transdermal gene-silencing nanoplatform that integrates metabolic regulation with anti-inflammatory therapy for precision psoriasis treatment.

Indexed as

Calcium phosphate nanoparticlesMicroneedlesPsoriasissiRNA deliverySLC31A1Transdermal therapy

Identifiers

PMID41809386
PMCPMC12969650

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.